Search

Your search keyword '"Usuda, Haruki"' showing total 155 results

Search Constraints

Start Over You searched for: Author "Usuda, Haruki" Remove constraint Author: "Usuda, Haruki"
155 results on '"Usuda, Haruki"'

Search Results

5. Dietary Fiber Deficiency Accelerates Colitis in Mice in the Short Term Independent of Short-Chain Fatty Acids.

6. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial

7. Association of Serum and Fecal Bile Acid Patterns With Liver Fibrosis in Biopsy-Proven Nonalcoholic Fatty Liver Disease: An Observational Study

10. Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease

12. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design

13. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial

16. Periodontal Treatment and Usual Care for Nonalcoholic Fatty Liver Disease: A Multicenter, Randomized Controlled Trial

18. Differential Expression of Pro-inflammatory and Pro-coagulant Genes in Endothelial Cells Induced by Porphyromonas gingivalis Lipopolysaccharide, Escherichia coli Lipopolysaccharide, and Zymosan

23. Endotoxins and Non-Alcoholic Fatty Liver Disease

24. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target

27. Gut microbiota composition associated with hepatic fibrosis in non‐obese patients with non‐alcoholic fatty liver disease

30. Efficacy of Bifidobacterium bifidum G9-1 in improving quality of life in patients with chronic constipation: a prospective intervention study

31. Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease

33. The benefit of elobixibat in chronic constipation is associated with faecal deoxycholic acid but not effects of altered microbiota

34. The efficacy of Bifidobacterium bifidum G9-1 in improving quality of life in patients with chronic constipation

37. Efficacy of Lubiprostone in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled, Phase 2A Trial

41. Histological Detection of mmcp-4 Expressing Cells by In Situ RT-PCR Method

43. GS-01-Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease: The LUBIPRONE, doubleblind, randomized, placebo-controlled, phase II study

44. FRI-312-Increased levels of bile acid in feces plays an important role in pathophysiology of non-alcoholic steatohepatitis

Catalog

Books, media, physical & digital resources